184 related articles for article (PubMed ID: 25118650)
1. Mis-sesnse mutations in Tafazzin (TAZ) that escort to mild clinical symptoms of Barth syndrome is owed to the minimal inhibitory effect of the mutations on the enzyme function: In-silico evidence.
Debnath S; Addya S
Interdiscip Sci; 2015 Mar; 7(1):21-35. PubMed ID: 25118650
[TBL] [Abstract][Full Text] [Related]
2. TAZ encodes tafazzin, a transacylase essential for cardiolipin formation and central to the etiology of Barth syndrome.
Garlid AO; Schaffer CT; Kim J; Bhatt H; Guevara-Gonzalez V; Ping P
Gene; 2020 Feb; 726():144148. PubMed ID: 31647997
[TBL] [Abstract][Full Text] [Related]
3. Tafazzin Mutation Affecting Cardiolipin Leads to Increased Mitochondrial Superoxide Anions and Mitophagy Inhibition in Barth Syndrome.
Petit PX; Ardilla-Osorio H; Penalvia L; Rainey NE
Cells; 2020 Oct; 9(10):. PubMed ID: 33096711
[TBL] [Abstract][Full Text] [Related]
4. The Function of Tafazzin, a Mitochondrial Phospholipid-Lysophospholipid Acyltransferase.
Schlame M; Xu Y
J Mol Biol; 2020 Aug; 432(18):5043-5051. PubMed ID: 32234310
[TBL] [Abstract][Full Text] [Related]
5. Tafazzin deficiency impairs CoA-dependent oxidative metabolism in cardiac mitochondria.
Le CH; Benage LG; Specht KS; Li Puma LC; Mulligan CM; Heuberger AL; Prenni JE; Claypool SM; Chatfield KC; Sparagna GC; Chicco AJ
J Biol Chem; 2020 Aug; 295(35):12485-12497. PubMed ID: 32665401
[TBL] [Abstract][Full Text] [Related]
6. Identification of novel mitochondrial localization signals in human Tafazzin, the cause of the inherited cardiomyopathic disorder Barth syndrome.
Dinca AA; Chien WM; Chin MT
J Mol Cell Cardiol; 2018 Jan; 114():83-92. PubMed ID: 29129703
[TBL] [Abstract][Full Text] [Related]
7. The lipid environment modulates cardiolipin and phospholipid constitution in wild type and tafazzin-deficient cells.
Oemer G; Koch J; Wohlfarter Y; Lackner K; Gebert REM; Geley S; Zschocke J; Keller MA
J Inherit Metab Dis; 2022 Jan; 45(1):38-50. PubMed ID: 34494285
[TBL] [Abstract][Full Text] [Related]
8. Barth syndrome: cellular compensation of mitochondrial dysfunction and apoptosis inhibition due to changes in cardiolipin remodeling linked to tafazzin (TAZ) gene mutation.
Gonzalvez F; D'Aurelio M; Boutant M; Moustapha A; Puech JP; Landes T; Arnauné-Pelloquin L; Vial G; Taleux N; Slomianny C; Wanders RJ; Houtkooper RH; Bellenguer P; Møller IM; Gottlieb E; Vaz FM; Manfredi G; Petit PX
Biochim Biophys Acta; 2013 Aug; 1832(8):1194-206. PubMed ID: 23523468
[TBL] [Abstract][Full Text] [Related]
9. Barth syndrome mutations that cause tafazzin complex lability.
Claypool SM; Whited K; Srijumnong S; Han X; Koehler CM
J Cell Biol; 2011 Feb; 192(3):447-62. PubMed ID: 21300850
[TBL] [Abstract][Full Text] [Related]
10. Experimental models of Barth syndrome.
Pu WT
J Inherit Metab Dis; 2022 Jan; 45(1):72-81. PubMed ID: 34370877
[TBL] [Abstract][Full Text] [Related]
11. Expression of human monolysocardiolipin acyltransferase-1 improves mitochondrial function in Barth syndrome lymphoblasts.
Mejia EM; Zegallai H; Bouchard ED; Banerji V; Ravandi A; Hatch GM
J Biol Chem; 2018 May; 293(20):7564-7577. PubMed ID: 29563154
[TBL] [Abstract][Full Text] [Related]
12. Barth Syndrome: Connecting Cardiolipin to Cardiomyopathy.
Ikon N; Ryan RO
Lipids; 2017 Feb; 52(2):99-108. PubMed ID: 28070695
[TBL] [Abstract][Full Text] [Related]
13. Substantial Decrease in Plasmalogen in the Heart Associated with Tafazzin Deficiency.
Kimura T; Kimura AK; Ren M; Berno B; Xu Y; Schlame M; Epand RM
Biochemistry; 2018 Apr; 57(14):2162-2175. PubMed ID: 29557170
[TBL] [Abstract][Full Text] [Related]
14. Loss of tafazzin results in decreased myoblast differentiation in C2C12 cells: A myoblast model of Barth syndrome and cardiolipin deficiency.
Lou W; Reynolds CA; Li Y; Liu J; Hüttemann M; Schlame M; Stevenson D; Strathdee D; Greenberg ML
Biochim Biophys Acta Mol Cell Biol Lipids; 2018 Aug; 1863(8):857-865. PubMed ID: 29694924
[TBL] [Abstract][Full Text] [Related]
15. Clinical presentation and natural history of Barth Syndrome: An overview.
Taylor C; Rao ES; Pierre G; Chronopoulou E; Hornby B; Heyman A; Vernon HJ
J Inherit Metab Dis; 2022 Jan; 45(1):7-16. PubMed ID: 34355402
[TBL] [Abstract][Full Text] [Related]
16. Barth syndrome: cardiolipin, cellular pathophysiology, management, and novel therapeutic targets.
Zegallai HM; Hatch GM
Mol Cell Biochem; 2021 Mar; 476(3):1605-1629. PubMed ID: 33415565
[TBL] [Abstract][Full Text] [Related]
17. Cardiolipin-deficient cells have decreased levels of the iron-sulfur biogenesis protein frataxin.
Li Y; Lou W; Grevel A; Böttinger L; Liang Z; Ji J; Patil VA; Liu J; Ye C; Hüttemann M; Becker T; Greenberg ML
J Biol Chem; 2020 Aug; 295(33):11928-11937. PubMed ID: 32636300
[TBL] [Abstract][Full Text] [Related]
18. Cardiolipin function in the yeast S. cerevisiae and the lessons learned for Barth syndrome.
Ji J; Greenberg ML
J Inherit Metab Dis; 2022 Jan; 45(1):60-71. PubMed ID: 34626131
[TBL] [Abstract][Full Text] [Related]
19. Seven functional classes of Barth syndrome mutation.
Whited K; Baile MG; Currier P; Claypool SM
Hum Mol Genet; 2013 Feb; 22(3):483-92. PubMed ID: 23100323
[TBL] [Abstract][Full Text] [Related]
20. Intrafamilial variability for novel TAZ gene mutation: Barth syndrome with dilated cardiomyopathy and heart failure in an infant and left ventricular noncompaction in his great-uncle.
Ronvelia D; Greenwood J; Platt J; Hakim S; Zaragoza MV
Mol Genet Metab; 2012 Nov; 107(3):428-32. PubMed ID: 23031367
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
